We are live on ! Find out more
AVEO

AVEO Pharmaceuticals

Delisted

AVEO was delisted on the 19th of January, 2023.

77 hedge funds and large institutions have $135M invested in AVEO Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,171% more call options, than puts

Call options by funds: $3.7M | Put options by funds: $291K

350% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 6

62% more capital inflows, than outflows

Capital inflows: $20.6M | Capital outflows: $12.7M

38% more funds holding

Funds holding: 56 → 77 (+21)

2.8% more ownership

Funds ownership: 44.71% → 47.5% (+2.8%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 17

Holders
77
Holders Change
+21
Holders Change %
+37.5%
% of All Funds
1.32%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
27
Increased
17
Reduced
17
Closed
6
Calls
$3.7​M
Puts
$291​K
Net Calls
+$3.41​M
Net Calls Change
+$641​K

AVEO Hedge Fund Activity: Q3 2022 in Review

77 of the 5,834 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals (AVEO) for Q3 2022, worth a combined $135M — up 34% from $101M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new AVEO positions and 6 closed out — a net gain of 21 holders — while 17 added to existing stakes and 17 trimmed.

The largest buyer was Rubric Capital Management (New York), adding an estimated $5.69M. The largest seller was J. Goldman & Co, cutting an estimated $5.09M.

  • 77 institutional investors held AVEO Pharmaceuticals (AVEO) as of Q3 2022, up from 56 in Q2 2022.
  • Funds reported $135M of AVEO Pharmaceuticals stock for Q3 2022, up 34% quarter-over-quarter.
  • 27 funds opened new AVEO Pharmaceuticals positions in Q3 2022 and 6 closed out, a net change of +21 holders.
  • The largest AVEO Pharmaceuticals buyer in Q3 2022 was Rubric Capital Management (New York), an estimated $5.69M added.
  • The largest AVEO Pharmaceuticals seller in Q3 2022 was J. Goldman & Co, an estimated $5.09M sold.

Based on aggregated 13F filings for Q3 2022.